# Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7

> **NCT02040402** · PHASE4 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 100 (actual)

## Conditions studied

- Infectious Disease

## Interventions

- **BIOLOGICAL:** 7-valent pneumococcal conjugated vaccine
- **BIOLOGICAL:** 7-valent pneumococcal conjugated vaccine

## Key facts

- **NCT ID:** NCT02040402
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040402, "Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02040402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*